IcoSema vs Insulin Efsitora Alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

IcoSema · Kyinsu

Marketed by Novo Nordisk

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05352815 · Phase 3 · completed

Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.

Reported efficacy

Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)

Result source: NCT06269107

Insulin Efsitora Alfa · Onswik

Marketed by Eli Lilly

Approved in Type 2 Diabetesprotein (Fc-fusion)
Partial signal

NCT05275400 · Phase 3 · completed

The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)

Result source: NCT05662332

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIcoSemaInsulin Efsitora Alfa
HbA1c, change-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394
Body weight, change (kg)-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033
3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785
HbA1c below 7%—Not posted · NCT05013229—Not reported
Fasting plasma glucose, change-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033
—Not reported
3-point MACE (% with event)—Not posted · NCT05013229—Not reported

HbA1c, change

IcoSema
-1.6% vs -0.9%vs Insulin Icodecwk 52 · n 598NCT05352815
2 other results
  • -1.4% vs -0.9% wk 52 · n 325 · Phase 3 · primary NCT05259033
  • -1.5% vs -1.4% wk 52 · Phase 3 · primary NCT05013229
Insulin Efsitora Alfa
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394

Body weight, change (kg)

IcoSema
-3.7 vs 2.0vs Insulin Icodecwk 52 · n 606NCT05352815
1 other result
  • 0.9 vs -3.8 wk 52 · n 325 · Phase 3 · secondary NCT05259033
Insulin Efsitora Alfa
3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785

HbA1c below 7%

IcoSema
—Not posted · NCT05013229
Insulin Efsitora Alfa
—Not reported

Fasting plasma glucose, change

IcoSema
-1.9 vs -1.6vs Insulin Icodecwk 52 · n 552NCT05352815
1 other result
  • -2.7 vs -1.4 wk 52 · n 313 · Phase 3 · secondary NCT05259033
Insulin Efsitora Alfa
—Not reported

3-point MACE (% with event)

IcoSema
—Not posted · NCT05013229
Insulin Efsitora Alfa
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. IcoSema: 6 of 7 rows · Insulin Efsitora Alfa: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIcoSemaInsulin Efsitora Alfa
Rows use multiple source trials
Time Above Range
absolute value · % of time
23.2 vs 36.7 Insulin Icodec % of time @ 52wka
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
29.66 vs 33.05 Insulin Degludec % of time @ 52wka
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below Range
absolute value · % of time
0.27 vs 0.33 Insulin Icodec % of time @ 52wka,b
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mLa,b
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1 other source trial
6.84 vs 5.25 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range
absolute value · percentage points
75.9% (n=481) vs 61.9% (n=488) Insulin Icodec @ 52wka
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
64.27% (n=387) vs 61.18% (n=381) Insulin Degludec @ 52wka
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Dropout rate
5.4%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
3.8%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%500 U/mLc
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
5.4%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
8.8%Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
12.6%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
12.9%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
—
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.1%500 U/mLc
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
0.6%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
0.7%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
0.8%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Serious AEs
9.2%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.7%500 U/mLc
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
8.8%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.7%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
7.1%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
5.2%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
6.1%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
nausea 23.8%
diarrhoea 15.8%
vomiting 10.6%
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
covid-19 15%
nausea 11.7%
diarrhoea 11.1%
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
500 U/mLc
covid-19 10.7%
nasopharyngitis 9.2%
dose calculation error 6.4%
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 7 more results
nasopharyngitis 9.2%
covid-19 7.9%
upper respiratory tract infection 7.9%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
anaemia 4.7%
arthralgia 2.3%
diarrhoea 2.3%
NCT04450394 · Phase 2 · registry result, not featured evidence
abdominal discomfort 7.1%
anaemia 7.1%
chest pain 7.1%
NCT04450394 · Phase 2 · registry result, not featured evidence
diarrhoea 6.7%
upper respiratory tract infection 5.9%
cough 0.7%
NCT03736785 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 10.6%
diarrhoea 6.1%
dizziness 5.3%
NCT03736785 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: baseline_threshold differs (bmi<=45 versus bmi<=40, hba1c<=10, hba1c>=7).
  2. bAssessment timepoints differ: 26 weeks versus 52 weeks.
  3. cPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

IcoSema

Fasting Plasma Glucose -1.9 vs -1.65 Insulin Icodec mmol/L @ 52wk
absolute change · mmol/L
NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-2.74 vs -1.41 Semaglutide mmol/L @ 52wk
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 or 3 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 2 15 vs 13 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 0 Semaglutide count @ 57wk
event count · count
NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

Insulin Efsitora Alfa

Fasting Glucose Change mg/dL -30.97 vs -30.13 Insulin Degludec mg @ 26wk500 U/mL
absolute change · mg
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
-46.76 vs -50.92 Glargine mg @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-30.87 vs -26.58 Insulin Glargine mg @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.1 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
-18.6 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
TRIM-D 10.03 vs 6.88 Insulin Degludec score @ 26wk500 U/mL
absolute change · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 3 more results
10.09 vs 6.53 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.33 vs 6.98 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 13.87 Glargine score @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 14.9 vs 12.3 Insulin Degludec score @ 26wk500 U/mL
absolute value · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
15.1 vs 12.3 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 11.7 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
FBG Change mg/dL -57.86 vs -63.04 Insulin Degludec mg @ 26wk
absolute change · mg
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-59.77 vs -59.97 Insulin Degludec mg @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Glucose Variability CV 26.31% (n=368) vs 26.67% (n=360) Insulin Degludec @ 26wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
26.29% (n=368) vs 26.81% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 70 mg/dL 1.06% (n=368) vs 0.93% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
1.55% (n=368) vs 1.25% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.49% (n=368) vs 1.19% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 54 mg/dL 0.24% (n=368) vs 0.27% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
0.33% (n=368) vs 0.28% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.32% (n=368) vs 0.3% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Event Incidence 25.94% (n=397) vs 29.9% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Nocturnal Hypoglycemia Incidence 3.53% (n=397) vs 5.03% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 15.1 vs 14.5 Glargine score @ 52wk
absolute value · score
Treatment satisfaction score
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DID-EQ Device Characteristics 91.4 vs 89.6 Glargine score @ 52wk
absolute change · score
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than 7 Without Nocturnal Hypoglycemia 38.6% (n=361) vs 35.9% (n=362) Insulin Glargine @ 26wk
responder rate · % of participants
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IcoSema's landscape · Insulin Efsitora Alfa's landscape